<a href="https://laohu8.com/S/RNA">Avidity Biosciences</a> Accelerates Executive Payouts Ahead of Novartis Merger
Avidity Biosciences Inc. has announced changes to executive compensation in connection with its pending merger with Novartis AG. The company’s board approved the accelerated vesting and payment of certain equity awards and annual cash bonuses for named executive officers, including Ms. Boyce, Dr. Flanagan, Ms. McCarthy, and Mr. Moriarty, as well as other executives. These payments, which would have otherwise been issued on or prior to the merger closing or in 2026, will now be paid out in December 2025. Each executive receiving these accelerated benefits has signed an agreement requiring repayment of the accelerated amounts if their employment ends under specified conditions before the original payment date or, in some cases, before December 31, 2029.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avidity Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-323363), on December 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.